| Related Articles |
Sinonasal malignancies: A population-based analysis of site-specific incidence and survival.
Laryngoscope. 2015 Nov;125(11):2491-7
Authors: Dutta R, Dubal PM, Svider PF, Liu JK, Baredes S, Eloy JA
Abstract
OBJECTIVES/HYPOTHESIS: Sinonasal malignancies vary in behavior according to histology and anatomical location. Incidence, survival, and optimal treatment for these lesions are thus uncertain in various cases. Our objective was to utilize a national population-based registry to identify the most common sinonasal histopathologies by anatomical site, and subsequently analyze the data by incidence trends, survival rates, patient demographics, and treatment modalities.
STUDY DESIGN: Retrospective analysis of the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry.
METHODS: The SEER database was examined for patients diagnosed with sinonasal malignancies between 1973 and 2011. Data were stratified according to anatomical site, incidence, survival, histology, staging, and patient demographics. Therapy-based outcomes were analyzed for cases from 1983 to 2011.
RESULTS: A total of 13,295 patients were identified, with an incidence of 0.83 per 100,000 people. Males comprised 58.6% of cases. Whites represented 81.5% of cases, while blacks comprised 8.7%. Squamous cell carcinoma was the most common histology (41.9%) across all sites of the sinonasal tract. The most common anatomical site of malignancy was the nasal cavity (45.7%), and least common was the frontal sinus (1.2%). For single sites, 5-year disease-specific survival (DSS) was highest for nasal cavity tumors (67.1%) and lowest for overlapping sinus malignancies (37.6%). The overall 5-year DSS for all sinonasal malignancies was 53.7%.
CONCLUSION: Sinonasal malignancies are rare entities with poor overall prognosis. By anatomical site, prognosis is best for nasal cavity cancers and worst for overlapping lesions.
LEVEL OF EVIDENCE: 4.
PMID: 26228792 [PubMed - indexed for MEDLINE]
from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/23qnXkN
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου